Methods of treating polycystic ovarian syndrome using chlorogenic acid and inositol
The invention provides a method of treating or preventing polycystic ovarian syndrome (PCOS) in a mammal, comprising administering chlorogenic acid and inositol in an amount effective to treat or prevent PCOS in the mammal. In an embodiment of the invention, the method further comprises administering L-cysteine to the mammal.
1. A method of treating or preventing polycystic ovarian syndrome (PCOS) in a mammal, the method comprising orally administering to the mammal a pharmaceutical composition comprising:
(i) chlorogenic acid in a daily dose of about 0.2 g to about 1.5 g,
(ii) cysteine in a daily dose of about 250 mg to about 1500 mg,
(iii) pomegranate extract in a daily dose of about 25 mg to about 1 g,
(iv) inositol in a daily dose of about 50 mg to about 4.0 g, and
(v) a pharmaceutically acceptable carrier,
to treat or prevent PCOS in the mammal.
2. The method of claim 1 , wherein the pharmaceutical composition is a solid pharmaceutical composition.
3. The method of claim 1 , wherein the inositol comprises myo-inositol.
4. The method of claim 1 , wherein the inositol comprises D-chiro-inositol.
5. The method of claim 1 , comprising administering chlorogenic acid in a daily dose of about 0.5 g to about 1.25 g.
6. The method of claim 1 , comprising administering chlorogenic acid in a daily dose of about 1 g.
7. The method of claim 1 , comprising administering cysteine in a daily dose of about 500 mg to about 1200 mg.
8. The method of claim 1 , comprising administering cysteine in a daily dose of about 600 mg.
9. The method of claim 1 , wherein the pharmaceutical composition is a capsule.
10. The method of claim 9 , wherein the capsule is a vegetarian capsule.
11. The method of claim 1 , wherein the cysteine comprises N-acetyl-L-cysteine (NAC), L-cysteine, or a combination thereof.
12. The method of claim 1 , wherein the pharmaceutical composition does not comprise any one or more of sugar, salt, starch, yeast, wheat, gluten, soy, milk, egg, shellfish, and preservatives.
13. The method of claim 1 , wherein the pharmaceutical composition comprises one or more of silica, cellulose, and vegetable polysaccharide.
14. The method of claim 1 , comprising administering inositol in a daily dose of about 100 mg to about 1.2 g.
15. The method of claim 1 , comprising administering inositol in a daily dose of about 200 mg.